In a single-arm phase 3b trial, Fasenra helped 62% of nearly 600 patients with severe asthma to go on about their lives without oral corticosteroids, AstraZeneca said Thursday. More patients, or 81%, had their daily steroid dose reduced to 5mg or below, including those who stopped use completely.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,